Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: rrufff who wrote (44012)	12/6/2005 7:13:30 PM
From: rrufff	Read Replies (1) \| Respond to of 120415

APNO - 1.50 + .11 - the PR was a good start. Spent some time on the phone with Daryl Ray. Got a feel that things are progressing on schedule. If you go through the merger documents, you see that the company was projected to be worth somewhere in the vague area of $2-$3 a share and XTRN was selling in that area. Don't forget the XTRN shareholders could have cashed out pretty close to that area. Under 10 million shares. Revenues for last year were $10.5 million and they were projecting 15% increase to a under $12 million. The PR indicates this is just the beginning. Alpha Innotech Announces Attainment of Key Milestones Tuesday December 6, 9:00 am ET SAN LEANDRO, Calif.--(BUSINESS WIRE)--Dec. 6, 2005--After completing the reverse merger with Xtrana on October 3, 2005 Alpha Innotech Corp. (OTCBB:APNO - News) today announced completion of the following key milestones: As previously announced, Alpha Innotech entered into a development, manufacturing and supply agreement with GE Healthcare for a full line of proprietary imaging systems. GE is exclusively selling these products worldwide under their brand name in the life science research market. Alpha Innotech initiated shipments of products in the third quarter of 2005 and will see increasing revenues from this agreement in the fourth quarter. First shipments were made of the new AlphaScan(TM) microarray scanner, a compact high performance slide-based scanner for microarray imaging and data analysis of DNA, protein, cell and tissue arrays. First shipments were also made of the new NovaRay® Detection Platform, designed to address the growing number of applications in the microarray market, including multiplexed arrays (few targets--many samples) for high throughput analysis of DNA. NovaRay can also be used to perform protein and cell array analyses in microplates and on other substrates. Introduced AlphaPart11Ease(TM), an innovative and comprehensive software package that enables digital image acquisition and analysis compliant with the electronic validation, audit trail, record retention, and record copying requirements of FDA regulations promulgated under 21 CFR Part 11. Following completion of the previously announced reverse merger transaction on October 3, 2005, trading began on the NASD Over-the-Counter Bulletin Board under the symbol APNO:BB. As of November 14, 2005, approximately 9,726,000 common shares were outstanding. According to Haseeb Chaudhry, Chief Executive Officer of Alpha Innotech, "Key components of our growth strategy include extension and expansion of existing distribution channels and the introduction of new products. The recently announced OEM agreement with GE Healthcare and the introduction of new products such as the NovaRay and AlphaScan systems are the first steps toward attaining this goal. We anticipate sales for the new products to be modest in 2005 and becoming a larger contributor to revenues in 2006." Mr. Chaudhry added, "With our new growth initiatives and product launches, combined with the increasing interest in drug development and life science research, we anticipate 2006 to be an active year for the company. We hope to strengthen the company and build shareholder value as we move forward into the new year." About Alpha Innotech Corp. Alpha Innotech Corp. is a supplier of innovative solutions for life science and drug discovery with core expertise in quantitative imaging, informatics, and molecular biology. Alpha Innotech maintains its corporate offices in San Leandro, CA and has customers served by a direct sales force and distributors located in over 40 countries around the world. For more information about Alpha Innotech, visit our website at www.alphainnotech.com Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. These forward-looking statements involve a number of risks and uncertainties that include, but are not limited to, the Company's need for additional financing, the timing of the introduction and success of new products, and the Company's growth prospects, that could cause actual results to differ materially from those anticipated by these forward-looking statements. Please also refer to the risk factors described in our filings with the Securities and Exchange Commission, including our recent Form 8-K and Form 10-QSB filed with the Securities and Exchange Commission. We assume no obligation to update the forward-looking information contained in this news release. Contact: Alpha Innotech Corp. Darryl Ray, 510-483-9620 -------------------------------------------------------------------------------- Source: Alpha Innotech Corp.